Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingGenetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Post author: Post published:March 17, 2026 Post category: Continue ReadingNonconforming Lisocabtagene Maraleucel Expanded Access Protocol
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingStudy of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Post author: Post published:March 17, 2026 Post category: Continue ReadingLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL Post author: Post published:March 17, 2026 Post category: Continue ReadingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Post author: Post published:March 1, 2026 Post category: Continue ReadingAutologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia Post author: Post published:March 1, 2026 Post category: Continue ReadingStudy of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Post author: Post published:March 1, 2026 Post category: Continue ReadingCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
